Chagas disease

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Administration, Nontuberculous mycobacteria, Conference, Bill, AN2, Entrepreneurship, NTM, Boron, Tuberculosis, University, Patient, Melioidosis, Data monitoring committee, G&A, MAC, Insurance, Infection, Wellcome Trust, Investment, Clinical trial, Chagas disease, Therapy, Malaria, Safety, Poster, Research and development, Mycobacteroides abscessus, IDSA, Trust, Pharmaceutical industry

Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.

Key Points: 
  • Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.
  • Net loss: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year.
  • Net loss for the fourth quarter of 2023 was $16.9 million, compared to $11.8 million for the same period during 2022.
  • Cash Position: The Company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.

Chagas Disease (T. cruzi Infection) Market: Comprehensive Global Analysis and Forecast Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Infectious Diseases, Pharmaceutical, Health, Pharmacy, Intelligence, Chagas disease, FDA, Infection, Epidemiology, ESG, Hospital, Health care, Bayer, Child, CDC, Movement, Trypanosoma cruzi, Research report, Nifurtimox, Vaccine

The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status.

Key Points: 
  • The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status.
  • It is widespread throughout 21 American countries, but it can spread to non-endemic nations worldwide through the movement of infected individuals.
  • The research report provides a thorough overview of the Chagas Disease market.
  • This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis.

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
Thursday, November 9, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MAC, Global health, Pivotal, Entrepreneurship, Therapy, Chagas disease, Investment, Clinical trial, Bill, Administration, Insurance, Patient, IDSA, NTM, AN2, University, Infection, Conference, Partnership, R, Research and development, Boron, Malaria, Poster, Melioidosis, Tuberculosis, Pharmaceutical industry, Life insurance, Pfizer, Chagas, Wellcome

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.
  • “We are incredibly proud of the significant milestones achieved recently and over the past quarter.
  • There is an urgent need for more effective, novel, oral agents for this difficult-to-treat disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer.
  • This resulted in aggregate gross proceeds to the Company of approximately $70.0 million, before deducting underwriting discounts and commissions and offering expenses.

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Retrieved on: 
Wednesday, October 18, 2023
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Primate, IND, Human, Chagas disease, Infection, Entrepreneurship, University, Tropics, Risk, Partnership, University of Georgia, Therapy, AN2, Pharmaceutical industry, Chagas, Pfizer, Wellcome

These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome.

Key Points: 
  • These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome.
  • The lead compound under this series, AN2-502998 (formerly known as AN15368), was discovered in close collaboration with Professor Rick Tarleton, Ph.D., University of Georgia, an expert in Chagas disease and Trypanosoma cruzi biology.
  • To date, preclinical activities have been supported using non dilutive grant funding from Wellcome and are conducted in partnership with Professor Tarleton.
  • I am optimistic that AN2-502998 has the potential to be a solution for those infected with T. cruzi and at risk for development of debilitating and life-threatening Chagas disease.”

Leprosy-causing bacteria found in armadillo specimens highlight value of museum collections for tracking pathogens

Retrieved on: 
Wednesday, April 26, 2023
Human, Natural history, Prevalence, Aerosol, SRL Diagnostics, Leprosy, Infection, Armadillo, Fungal infection, Mycobacterium leprae, Research, Paratriathlon, Chagas disease, Mycobacterium lepromatosis, Paralysis, Incidence, Animal, Spleen, Patient, Time, Museum, Water, Bacteria, Nerve, Environment, Disease, Vaccine, Pharmaceutical industry

Since 2010, evidence has accumulated that the nine-banded armadillo, Dasypus novemcinctus, is transmitting leprosy to people in North America and potentially elsewhere.

Key Points: 
  • Since 2010, evidence has accumulated that the nine-banded armadillo, Dasypus novemcinctus, is transmitting leprosy to people in North America and potentially elsewhere.
  • In our study, we used online repositories such as VertNet to identify armadillo specimens held by museums.
  • But this bacteria has infected humans in Mexico, Colombia, Canada and elsewhere, along with red squirrels in the British Isles.
  • Our work is another case study demonstrating that natural history collections can play an important role in human infectious disease research.

Africa In Vitro Diagnostics Market Report 2023: A $1.78 Billion Market by 2029 - Key Market Players' Increasing Investments Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, April 3, 2023
Health, Biotechnology, Prevalence, HIV, COVID-19, Chagas, Infection, Chagas disease, Hospital, Fever Dream, IVD, Conditional sentence, Diagnosis, Geography, Medical device, Pharmaceutical industry

Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.

Key Points: 
  • Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.
  • Based on product category, in 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Africa IVD market.
  • Based on technology, in 2022, the immunoassay segment is expected to account for the largest share of the Africa IVD market.
  • Based on application, in 2022, the infectious diseases segment is expected to account for the largest share of the Africa IVD market.

Antiparasitic Drugs Global Market Report 2022: Government, Non-Profit and Market Player Initiatives to Boost Adoption Bode Well For Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Health, Pharmaceutical, Product type, Route of administration, Chagas disease, Animal, Novartis, Malaria, Leishmaniasis, Infection, CAGR, Industry, Region, Trypanocidal agent, Parasitism, Merck Group, Aurobindo Pharma, Sun Pharma, Application, GlaxoSmithKline, Marketing, Lupinus, Cadila Pharmaceuticals, Viatris, US, Amazon Malaria Initiative, Wickham Laboratories Ltd, PMI, Administration, Renewable energy, Pharmaceutical industry, Protozoa, Parasitic worm

These infections result from parasites, which are tiny organisms that live on or inside people and animals.

Key Points: 
  • These infections result from parasites, which are tiny organisms that live on or inside people and animals.
  • There are various antiparasitic drugs, each drug targets a specific parasite.
  • Antiparasitic drugs treat several kinds of infections that result from a thousand types of parasites.
  • This would in turn increase demand for antiparasitic drugs and hence fuel growth of the global antiparasitic drugs market over the forecast period.

Ehrlich Pest Control's Top Five Creepy Pests this Halloween Season

Retrieved on: 
Monday, October 24, 2022
LinkedIn, Mecoptera, Nausea, Fluid mechanics, Science, Feces, Reptile, Bird, District, Pulse, Degenerative disease, TAP, Bee, House, Blood, Swelling, Pain, Chagas disease, Environment, Maintenance, Scorpion, Pest control, Caterpillar, Solution, Human, Trapping, Agriculture, Cochineal, Rentokil Initial, Facebook

READING, Pa., Oct. 24, 2022 /PRNewswire/ -- With Halloween rapidly approaching, people are gearing up to present their scariest costumes and scenes. Few things can cause a person's heart to skip a beat like a slithering, crawling pest. As part of this year's spooky season, Ehrlich Pest Control compiled a list of its top five nightmare-inducing pests.

Key Points: 
  • As part of this year's spooky season, Ehrlich Pest Control compiled a list of its top five nightmare-inducing pests.
  • Thomas Dobrinska, a board-certified entomologist for Ehrlich Pest Control, provided his five creepiest pests for this Halloween season.
  • Top five pests to watch out for this Halloween season:
    Triatomine "kissing" bug:This nocturnal pest feeds on the blood of almost anything with a pulse.
  • Rentokil and its companies, including Florida Pest Control, Western Exterminator and Presto-X Pest Control, provide commercial and residential pest control to customers in the United States and Canada.

7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease

Retrieved on: 
Monday, August 1, 2022
Vaccine, Parasitism, University, GLOBE, Research, Chagas disease, Arrhythmia, CEO, National Institute of Allergy and Infectious Diseases, National Institute, Risk, Infection, Integrin, Howard Brody, Cancer, Technology, Galveston National Laboratory, UTMB, Heart failure, Death, Korea Disease Control and Prevention Agency, Microbiology, Center, Trypanosoma cruzi, Pharmaceutical industry, Chagas, TC

Chagas disease is one of five Neglected Parasitic Infections prioritized by the Centers for Disease Control and Prevention.

Key Points: 
  • Chagas disease is one of five Neglected Parasitic Infections prioritized by the Centers for Disease Control and Prevention.
  • Chagas disease infection can cause cardiac arrhythmias and heart failure, leading to over 50,000 deaths per year worldwide.
  • The annual economic burden of Chagas disease is estimated at over $7 billion.
  • Dr. Gargs lab developed a novel DNA-based vaccine to protect against Tc infection, which was tested in preclinical models in combination with 7HPs lead, clinical-stage oral immunostimulant.

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Retrieved on: 
Wednesday, April 20, 2022
Protein, Eli Lilly and Company, Hepatitis, Clinical trial, Climate change, Tropical disease, Benevolence, COVID-19, Chagas disease, Genetics, WHO, Research, R, Infection, Mycetoma, Drug discovery, Probability, Patient, Drug combination, Fexinidazole, World, Fever Dream, Technology, Chemistry, World Health Organization, Drugs for Neglected Diseases Initiative, Leishmaniasis, Public health, Dengue fever, Partnership, FDA, Disease, Trypanosomiasis, Vaccine, Pharmaceutical industry

LONDON, April 20, 2022 /PRNewswire/ -- BenevolentAI, a leading clinical-stage artificial intelligence (AI) enabled drug discovery company, and Drugs for Neglected Disease initiative (DNDi), a not-for-profit research and development (R&D) organisation focusing on neglected diseases, today announced they have begun a joint research project to tackle dengue, one of the world's most prevalent infectious diseases. 

Key Points: 
  • BenevolentAI's research prompted global clinical trials, which resulted in the drug being approved for emergency use by the FDA.
  • The most promising drug candidates identified in the joint research project will later be tested in clinical trials in collaboration with dengue-endemic country partners.
  • BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.
  • BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.